Enristas 1MF Tablet PR is a combination oral antidiabetic medication containing Glimepiride 1mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, enhances pancreatic beta-cell insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily decreases hepatic glucose production and increases peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. The synergistic action of these agents provides effective glycemic regulation in patients inadequately controlled by diet, exercise, and monotherapy. Enristas 1MF Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is essential to monitor blood glucose levels regularly to assess therapeutic response and adjust dosage accordingly. Contraindications include type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Caution is advised in patients with cardiovascular disease or those undergoing radiologic studies involving iodinated contrast agents. Common adverse effects may include hypoglycemia, gastrointestinal disturbances such as nausea and diarrhea, and rarely lactic acidosis. Patient education on recognizing hypoglycemia symptoms and adherence to prescribed therapy is crucial for optimal outcomes.